CMAX CareMax Inc

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 09, 2023

 

 

CareMax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-39391	85-0992224
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1000 NW 57 Court Suite 400
Miami, Florida				33126
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 786 360-4768

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, par value $0.0001 per share		CMAX		The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share		CMAXW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

---

Item 2.02 Results of Operations and Financial Condition.

 

The information contained in Item 7.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

On August 9, 2023, CareMax, Inc., a Delaware corporation (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2023 and provided an investor presentation to accompany the press release. Copies of the press release announcing the Company's financial results and the investor presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

This information and the information contained in Exhibits 99.1 and 99.2 are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

		Exhibit Index
Exhibit No.			Description
99.1			Press Release issued by CareMax, Inc. on August 9, 2023
99.2			Investor Presentation of CareMax, Inc. on August 9, 2023
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 9, 2023	By:	/s/ Kevin Wirges
			Name: Kevin Wirges Title: Executive Vice President, Chief Financial Officer and Treasurer

 

---

 

 

EX-99.1

 

CareMax Reports Second Quarter 2023 Results

Miami, FL - August 9, 2023 - CareMax, Inc. (NASDAQ: CMAX; CMAXW) (“CareMax” or the “Company”), a leading technology-enabled value-based care delivery system, today announced financial results for the second quarter ended June 30, 2023.

“We continued to deliver on our growth strategy, ending the quarter with 102,500 Medicare Advantage members, up 177% year-over-year, and have confidence in achieving both our near and long-term membership targets that we announced at our investor day in March. Our second quarter performance was strong, excluding the impact of an unfavorable $7 million prior year development related to a Medicaid contract from 2022. Looking ahead, we are encouraged by the underlying performance of our business in the first half of the year and are raising our full year 2023 revenue guidance while reaffirming our adjusted EBITDA guidance range,” said Carlos de Solo, Chief Executive Officer.

Mr. de Solo continues, “At CareMax, our mission is to provide better care to seniors across the country. We believe our fully-integrated care model, powered by our proprietary built technology platform and highly scalable operating model, positions us well to achieve the long term goals we announced in March. We are excited for the next few years as we expect to continue to accelerate our growth and expand access to high-quality care for seniors nationwide.”

Second Quarter 2023 Results

Financial Outlook for Full Year 2023

CareMax is raising the following full year 2023 financial guidance:

CareMax is reaffirming the following full year 2023 financial guidance:

 

---

 

 

1 Adjusted EBITDA and Platform Contribution are non-GAAP financial metrics. A reconciliation of non-GAAP metrics to the most directly comparable GAAP financial measures is included in the appendix to this earnings release. Beginning with the three months ended June 30, 2023, the Company has updated its calculation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs adjustment. Adjusted EBITDA as previously reported for the second quarter of 2022 included an addback of $0.7 million for stay-on bonuses and duplicative salaries. Adjusted EBITDA as previously reported for the year ended December 31, 2022 included an addback of $2.9 million for stay-on bonuses and duplicative salaries.

2 De novo pre-opening costs represent (1) incremental payroll costs from employees specifically associated with the operational, contractual, physical, or regulatory infrastructure for de novo centers, prior to their opening; (2) legal costs directly associated with the de novo centers, incurred prior to their opening, which includes services such as execution of leases, health plan contracts and other agreements; (3) other expenses related to diligence, design, permitting, and other “soft costs” at new sites; and (4) rent and facility expenses prior to center opening. De novo post-opening losses include center-level operating losses recognized at a de novo center until the center breaks even, up to 18 months after opening, which consist of revenue, external provider costs and cost of care allocated for the de novo center.

 

Conference Call Details

Management will host a conference call at 8:30 am ET today to discuss the results. The conference call can be accessed by dialing (888) 330-2508 for U.S. participants, or (240) 789-2735 for international participants, and referencing conference ID 7874605. A live audio webcast as well as related presentation materials will also be available on the “Events & Presentations” section of CareMax’s investor relations website at ir.caremax.com. Following the live call, a replay will be available on the Company's website.

About CareMax

Founded in 2011, CareMax is a value-based care delivery system that utilizes a proprietary technology-enabled platform and multi-specialty, whole person health model to deliver comprehensive, preventative and coordinated care for its members. With over 200,000 Medicare Value-Based Care Members across 10 states, and fully integrated, Five-Star Quality rated health and wellness centers, CareMax is redefining healthcare across the country by reducing costs, improving overall outcomes and promoting health equity for seniors. Learn more at www.caremax.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, strategy and financial performance. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, the Company’s ability to integrate acquired businesses, including the ability to implement business plans, forecasts, and other expectations after the completion of the Steward transaction; the failure to realize anticipated benefits of the Steward transaction or to realize estimated pro forma results and underlying assumptions; the impact of COVID-19 or any variant thereof or any other pandemic or epidemic on the Company's business and results of operation; the Company’s ability to attract new patients; the availability of sites for de novo centers and the costs of opening such de novo centers; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to the Company's services; the Company's ability to continue its growth, including in new markets; changes in laws and regulations applicable to the Company's business, in particular with

 

---

 

 

respect to Medicare Advantage and Medicaid; the Company's ability to maintain its relationships with health plans and other key payers; any delay, modification or cancellation of government contracts; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs and the Company’s ability to comply with the covenants under the agreements governing its indebtedness; the Company’s ability to address the material weakness in its internal control over financial reporting; the Company's ability to recruit and retain qualified team members and independent physicians; risks related to future acquisitions; the Company’s ability to develop and maintain proper and effective internal control over financial reporting and the impact of any prior period developments. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's reports filed with the SEC. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law, and forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release.

 

Use of Non-GAAP Financial Information

Certain financial information and data contained in this press release is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this press release, such as Adjusted EBITDA and Platform Contribution and margin thereof have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company’s management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.

The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. For this reason, these non-GAAP measures may not be comparable to other companies’ similarly labeled non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results.

A reconciliation for Adjusted EBITDA and Platform Contribution to the most directly comparable GAAP financial measures is included below. A reconciliation of projected 2023 Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this press release because, without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

Use of Pro Forma Financial Information and Pro Forma Non-GAAP Financial Information

Certain of the information presented in the Non-GAAP Financial Summary and in the reconciliations to non-GAAP financial measures includes pro forma information derived from the unaudited pro forma statements of operations which are provided for informational purposes only and are not necessarily indicative of the operating results or financial position that would have occurred if the acquisitions of IMC and Care Holdings had occurred in the stated historical periods, nor are they indicative of the future results or financial position of the combined company. The unaudited pro forma statements of

 

---

 

 

operations do not give effect to the potential impact of any anticipated synergies, operating efficiencies or cost savings that may result from the acquisitions of IMC and Care Holdings, any integration costs or tax deductibility of transaction costs.

Additionally, Adjusted EBITDA presented on a pro forma basis gives effect to the acquisitions of IMC and Care Holdings as if they had occurred in historical periods. Such non-GAAP financial measures do not necessarily reflect what the Company’s Adjusted EBITDA would have been had the acquisitions occurred on the dates indicated.

 

 

---

 

 

CAREMAX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

(Unaudited)

		June 30, 2023				December 31, 2022
ASSETS
Current Assets
Cash and cash equivalents		$	54,605			$	41,626
Accounts receivable, net			159,812				151,036
Risk settlement assets			717				707
Other current assets			3,516				3,968
Total Current Assets			218,650				197,336
Property and equipment, net			24,628				21,006
Operating lease right-of-use assets			131,207				108,937
Goodwill, net			602,643				700,643
Intangible assets, net			112,537				123,585
Deferred debt issuance costs			1,052				1,685
Other assets			60,249				17,550
Total Assets		$	1,150,965			$	1,170,743
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable		$	8,677			$	7,687
Accrued expenses			12,634				16,854
Risk settlement liabilities			15,656				14,171
Related party liabilities			13,410				1,777
Related party debt, net			32,997				30,277
Current portion of third-party debt, net			276				253
Current portion of operating lease liabilities			7,116				5,512
Other current liabilities			7,303				790
Total Current Liabilities			98,069				77,322
Derivative warrant liabilities			2,434				3,974
Long-term debt, net			298,481				230,725
Long-term operating lease liabilities			116,187				96,539
Contingent earnout liability			-				134,561
Other liabilities			11,297				8,075
Total Liabilities			526,469				551,196
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock (1,000,000 shares authorized; one share issued and outstanding as of June 30, 2023 and December 31, 2022)			-				-
Class A common stock ($0.0001 par value; 250,000,000 shares authorized; 112,072,237 and 111,332,584 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively)			11				11
Additional paid-in-capital			776,533				657,126
Accumulated deficit			(152,048	)			(37,590	)
Total Stockholders' Equity			624,496				619,547
Total Liabilities and Stockholders' Equity		$	1,150,965			$	1,170,743

 

 

---

 

 

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(Unaudited)

	Three Months Ended June 30,								Six Months Ended June 30,
	2023				2022				2023				2022
Revenue
Medicare risk-based revenue	$	155,486			$	143,664			$	277,079			$	251,410
Medicaid risk-based revenue		30,054				19,896				55,680				40,062
Government value-based care revenue		22,206				-				32,216				-
Other revenue		16,694				8,719				32,449				17,727
Total revenue		224,440				172,279				397,424				309,199
Operating expenses
External provider costs		156,995				120,348				267,668				213,204
Cost of care		40,192				30,364				78,819				57,712
Sales and marketing		3,327				2,299				7,092				5,600
Corporate, general and administrative		20,795				18,063				44,739				37,041
Depreciation and amortization		6,828				4,903				13,404				9,965
Goodwill impairment		-				-				98,000				-
Acquisition related costs		54				2,789				74				3,055
Total operating expenses		228,191				178,767				509,797				326,577
Operating loss		(3,750	)			(6,488	)			(112,373	)			(17,378	)
Nonoperating income (expense)
Interest expense		(13,197	)			(3,896	)			(23,908	)			(5,624	)
Change in fair value of derivative warrant liabilities		434				7,391				1,540				3,855
Gain (loss) on remeasurement of contingent earnout liabilities		(16,220	)			-				19,916				-
Loss on extinguishment of debt, net		-				(6,172	)			-				(6,172	)
Other income (expense), net		534				(45	)			721				(507	)
		(28,449	)			(2,722	)			(1,730	)			(8,448	)
Loss before income tax		(32,199	)			(9,210	)			(114,103	)			(25,826	)
Income tax expense		(177	)			(171	)			(355	)			(351	)
Net loss	$	(32,376	)		$	(9,381	)		$	(114,458	)		$	(26,178	)
Weighted-average basic shares outstanding		111,671,302				87,422,917				111,511,214				87,395,596
Weighted-average diluted shares outstanding		111,671,302				87,422,917				111,511,214				87,395,596
Net loss per share
Basic	$	(0.29	)		$	(0.11	)		$	(1.03	)		$	(0.30	)
Diluted	$	(0.29	)		$	(0.11	)		$	(1.03	)		$	(0.30	)

 

 

---

 

 

 

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

		Six Months Ended June 30,
		2023				2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(114,458	)		$	(26,178	)
Adjustments to reconcile net loss to cash and cash equivalents
Depreciation and amortization expense			13,404				9,965
Amortization of debt issuance costs and discounts			4,086				753
Stock-based compensation expense			4,762				3,875
Income tax provision			355				351
Change in fair value of derivative warrant liabilities			(1,540	)			(3,855	)
Loss (gain) on remeasurement of contingent earnout liabilities			(19,916	)			-
Loss (gain) on extinguishment of debt			-				6,172
Payment-in-kind interest expense			5,500				1,078
Provision for credit losses			57				-
Goodwill impairment			98,000				-
Amortization of right-of-use assets			5,842				-
Other non-cash, net			1,213				60
Changes in operating assets and liabilities:
Accounts receivable			(1,255	)			(29,976	)
Other current assets			452				(504	)
Risk settlement assets and liabilities			1,968				19
Other assets			(41,807	)			(105	)
Operating lease liabilities			(4,959	)			-
Accounts payable			(128	)			5,273
Accrued expenses			(4,219	)			4,910
Related party liabilities			(1,134	)			-
Other liabilities			10,515				764
Net cash used in operating activities			(43,263	)			(27,398	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment			(5,234	)			(2,893	)
Net cash used in investing activities			(5,234	)			(2,893	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from borrowings on long-term debt, net			62,000				184,000
Principal payments of debt			(125	)			(121,881	)
Payments of debt issuance costs			(398	)			(6,174	)
Collateral for letters of credit			-				(5,439	)
Net cash provided by financing activities			61,477				50,505
NET INCREASE IN CASH AND CASH EQUIVALENTS			12,980				20,214
Cash and cash equivalents - beginning of period			41,626				47,917
CASH AND CASH EQUIVALENTS - END OF PERIOD		$	54,605			$	68,130

 

 

---

 

 

	Three Months Ended
Non-GAAP Financial Summary*	Pro Forma**
(in thousands)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Medicare risk-based revenue	$	66,618		$	76,428		$	91,277		$	107,747		$	143,664		$	122,267		$	113,041		$	121,593		$	155,486
Medicaid risk-based revenue		20,454			20,884			20,160			20,165			19,896			19,852			36,620			25,626			30,054
Government value-based care revenue		-			-			-			-			-			-			-			10,010			22,206
Other revenue		4,839			7,308			6,869			9,008			8,719			15,551			14,602			15,754			16,694
Total revenue		91,911			104,620			118,306			136,920			172,279			157,670			164,263			172,983			224,440
External provider costs		70,466			73,329			79,724			92,856			120,348			106,900			104,078			110,673			156,995
Cost of care		13,246			20,315			22,606			26,854			30,293			30,150			34,581			37,627			38,865
Platform contribution		8,199			10,976			15,977			17,210			21,638			20,620			25,604			24,683			28,580
Platform contribution margin (%)		8.9	%		10.5	%		13.5	%		12.6	%		12.6	%		13.1	%		15.6	%		14.3	%		12.7	%
Sales and marketing		1,688			1,274			2,615			3,301			2,299			2,355			3,806			3,765			3,381
Corporate, general and administrative		7,589			9,715			11,228			10,873			12,165			13,877			17,263			21,329			18,158
Adjusted operating expenses		9,277			10,988			13,843			14,174			14,464			16,232			21,069			25,094			21,539
Adjusted EBITDA	n/a			$	(13	)	$	2,134		$	3,035		$	7,175		$	4,388		$	4,535		$	(411	)	$	7,042
Pro Forma Adjusted EBITDA	$	(1,078	)	n/a			n/a			n/a			n/a			n/a			n/a			n/a			n/a
* For period ended June 30, 2021, figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred on January 1, 2021.
** For period ended June 30, 2021, the measure was calculated in a manner consistent with the concepts of Article 8 of Regulation S-X and represents Pro Forma Platform Contribution.

 

Reconciliation to Adjusted EBITDA and Pro Forma Adjusted EBITDA*	Three Months Ended
(in thousands)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Net Income (loss)	$	10,057		$	(14,479	)	$	(3,553	)	$	(16,797	)	$	(9,381	)	$	(22,052	)	$	10,434		$	(82,082	)	$	(32,376	)
Interest expense		792			1,291			1,905			1,728			3,896			6,076			8,542			10,711			13,197
Depreciation and amortization		1,437			5,176			6,089			5,062			4,903			4,573			7,180			6,576			6,828
Remeasurement of warrant and contingent earnout liabilities		(19,215	)		1,398			(8,734	)		3,536			(7,391	)		7,331			(84,171	)		(37,242	)		15,786
Goodwill impairment		-			-			-			-			-			-			70,000			98,000			-
Stock-based compensation		-			966			375			1,087			2,788			3,611			2,786			2,298			2,464
Loss (gain) on extinguishment of debt, net		(1,358	)		(279	)		7			-			6,172			-			-			-			-
Business Combination integration costs (1)		3,278			3,176			2,277			4,379			1,887			2,586			163			716			686
Acquisition and integration related costs (2)		3,806			1,871			2,325			3,429			4,074			2,118			10,632			622			815
DeSpac costs		4,721			27			742			9			10			11			10			-			-
Other (3)		(1,203	)		840			543			421			46			(46	)		(967	)		(187	)		(535	)
Income tax provision (benefit)		-			-			159			181			171			181			(20,074	)		177			177
Adjusted EBITDA	n/a			$	(13	)	$	2,134		$	3,035		$	7,175		$	4,388		$	4,535		$	(411	)	$	7,042
Pro forma adjustments (4)		(3,393	)		-			-			-			-			-			-			-			-
Pro forma Adjusted EBITDA	$	(1,078	)	n/a			n/a			n/a			n/a			n/a			n/a			n/a			n/a
* For period ended June 30, 2021, figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred on January 1, 2021. The Company has updated its calculation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs adjustment.
Memo:
De novo pre-opening costs	$	19		$	544		$	806		$	973		$	506		$	2,426		$	3,205		$	1,975		$	1,560
De novo post-opening costs		364			195			489			1,119			993			1,533			2,274			3,885			4,228

 

 

	Three Months Ended
(in thousands)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Consulting and legal fees (a)	$	3,142		$	2,204		$	1,639		$	3,190		$	887		$	725		$	257		$	282		$	237
Severance costs		-			-			949			25			252			1,080			167			11			13
Other (b)		137			972			(311	)		1,164			748			782			(261	)		423			436
	$	3,278		$	3,176		$	2,277		$	4,379		$	1,887		$	2,586		$	163		$	716		$	686

 

 

---

 

 

(a) Represents consulting and legal costs directly associated with efforts related to integration of the two privately held companies that were combined in the Business Combination.

(b) Represents primarily vendor expenses identified as temporary or duplicative and/or expenses outside the ordinary course of business and not necessary to run the Company's business.

 

	Three Months Ended
(in thousands)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Advisor and other professional fees (a)	$	3,257		$	1,183		$	1,183		$	1,622		$	2,359		$	1,219		$	9,877		$	(258	)	$	(34	)
Compensation costs (b)		549			688			1,142			1,808			1,715			899			755			880			849
	$	3,806		$	1,871		$	2,325		$	3,429		$	4,074		$	2,118		$	10,632		$	622		$	815

 

(a) Includes payments to our third-party transaction advisory firm associated with transaction contracts, including the Steward transaction that was closed in November 2022. Also, costs include legal and accounting fees directly associated with contemplated or closed transactions.
(b) Includes incremental payroll compensation expense for employees directly associated with services to achieve synergies related to closed transactions.

 

	Three Months Ended
(in thousands)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Subrogation income	$	(1,000	)	$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	-
Software sale		-			-			-			-			-			-			(1,000	)		-			-
Tax-related costs		-			266			95			265			69			(178	)		46			-			-
Legal settlement		-			75			229			-			(43	)		-			-			-			-
Interest income		-			-			-			-			-			-			-			(253	)		(602	)
Other		(203	)		499			219			156			19			133			(13	)		66			67
	$	(1,203	)	$	840		$	543		$	421		$	46		$	(46	)	$	(967	)	$	(187	)	$	(535	)

 

(4) Components of the pro forma adjustments were as follows:

(in thousands)			Three Months Ended June 30, 2021
IMC Adjusted EBITDA prior to the Business Combination(a)			$	(3,460	)
Care Holdings Adjusted EBITDA prior to the Business Combination(a)				55
Other pro forma adjustments				12
Total pro forma adjustments			$	(3,393	)

 

(a) The following table provides a reconciliation of net income (loss), the most closely comparable GAAP financial measure, to Adjusted EBITDA, for the results of IMC and Care Holdings prior to the Business Combination.

 

	Three Months Ended June 30, 2021
(in thousands)	IMC			Care Holdings
Net income (loss)	$	(6,151	)	$	55
Depreciation and amortization		1,066			-
Interest expense		1,625			-
Adjusted EBITDA	$	(3,460	)	$	55

 

 

	Pro Forma**
Non-GAAP Operating Metrics	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Centers		34			40			45			48			48			51			62			62			62
Markets		2			3			4			6			6			7			7			7			7
Patients (MCREM)*		35,300			40,400			50,100			50,600			54,000			57,400			221,500			225,100			226,500
Patients in value-based care arrangements (MCREM)		84.1	%		87.2	%		79.3	%		79.8	%		81.0	%		78.2	%		97.6	%		99.0	%		99.4	%
Platform Contribution ($, millions)**	$	8.2		$	11.0		$	16.0		$	17.2		$	21.6		$	20.6		$	25.6		$	24.7		$	28.6
* MCREM defined as Medicare Equivalent Members, which assumes the level of support received by a Medicare patient is equivalent to that received by three Medicaid or Commercial patients.
** For period ended June 30, 2021, the measure was calculated in a manner consistent with the concepts of Article 8 of Regulation S-X and represents Pro Forma Platform Contribution.

 

 

 

---

 

 

Reconciliation to Platform Contribution and Pro forma Platform Contribution

 

(in millions)	Jun 30, 2021			Sep 30, 2021			Dec 31, 2021			Mar 31, 2022			Jun 30, 2022			Sep 30, 2022			Dec 31, 2022			Mar 31, 2023			Jun 30, 2023
Gross profit (a)	$	0.1		$	4.5		$	9.6		$	11.2		$	15.4		$	14.8		$	17.2		$	17.1		$	20.4
Depreciation and amortization		1.4			5.2			6.1			5.1			4.9			4.6			7.2			6.6			6.8
Stock-based compensation		-			-			0.1			0.4			1.3			1.2			1.2			1.0			1.3
Pro forma adjustments (b)		6.7			-			-			-			-			-			-			-			-
Other adjustments (c)		-			1.3			0.2			0.5			0.1			0.1			-			-			-
Pro forma Platform Contribution	$	8.2		n/a			n/a			n/a			n/a			n/a			n/a			n/a			n/a
Platform Contribution	n/a			$	11.0		$	16.0			17.2		$	21.6		$	20.6		$	25.6		$	24.7		$	28.6
(a) Gross profit reflects the reclassification of stock-based compensation expense previously included in corporate, general and administrative expenses, which decreased gross profit by $0.1 million during the three months ended December 31, 2021, $0.4 million during the three months ended March 31, 2022, $1.3 million during the three months ended June 30, 2022, $1.2 million during the three months ended September 30, 2022, and $1.2 million during the three months ended December 31, 2022.
(b) Pro Forma adjustments are computed in a manner consistent with the concepts of Article 8 of Regulation S-X and give effect to the Business Combinations of IMC and Care Holdings as if they had occurred on January 1, 2021. Components of the pro forma adjustments were as follows:
	Three Months Ended June 30, 2021
(in thousands)	IMC			Care Holdings			Total
Gross profit prior to Business Combination	$	4,682		$	932		$	5,614
Depreciation and amortization prior to Business Combination		1,066			1			1,067
Pro forma adjustment	$	5,748		$	933		$	6,681
(c) Other adjustments include incremental costs primarily related to post-Business Combination integration initiatives. Other adjustments reflected during the three months ended September 30, 2021 include $0.6 million of incremental costs relating to one-time operational projects and $0.3 million of non-cash true-up of deferred rent expense. Other adjustments reflected during the three months ended March 31, 2022 include $0.3 million of costs for a pilot project regarding outsourcing.

 

Calculation of the Medical Expense Ratio

 

	Three Months Ended June 30,							Six Months Ended June 30,
	2023			2022				2023			2022
External provider costs	$	156,995		$	120,348			$	267,668		$	213,204
Medicare and Medicaid risk-based revenue		185,540			163,560				332,759			291,472
Medical Expense Ratio		84.6	%		73.6	%			80.4	%		73.1	%

 

Contacts:

 

Investor Relations

Samantha Swerdlin

VP, Investor Relations

ir@caremax.com

 

Media

Jaime Ameglio

Marketing & Communications Director

media@caremax.com

 

---

Second Quarter 2023 Earnings Presentation August 9, 2023 EX-99.2

---

Disclaimer Presentation This presentation (“Presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments, of CareMax, Inc. (“CareMax” or the “Company”) or any of its affiliates. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. CareMax assumes no obligation to update any information in this Presentation, except as required by law. Except as otherwise stated herein, references to "CareMax" for periods prior to June 8, 2021 refer to CareMax Medical Group, LLC prior to the business combination with Deerfield Healthcare Technology Acquisitions Corp. and IMC Holdings LLC ("IMC"). Projections This Presentation contains projected financial information. Such projected financial information constitutes forward-looking information, is for illustrative purposes only and should not be relied upon as indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the projected financial information. See “Forward Looking Statements” paragraph below. Actual results may differ materially from the results contemplated by the projected financial information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such projections will be achieved. The independent registered public accounting firm of CareMax has not audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and, accordingly, has not expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation. Forward-Looking Statements This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and strategy and future financial results. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," “pro-forma,” "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this Presentation. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, the Company’s ability to integrate acquired businesses, including the ability to implement business plans, forecasts, and other expectations after the completion of the Steward transaction; the failure to realize anticipated benefits of the Steward transaction or to realize estimated pro forma results and underlying assumptions; the impact of COVID-19 or any variant thereof or any other pandemic or epidemic on the Company's business and results of operation; the Company’s ability to attract new patients; the availability of sites for de novo centers and the costs of opening such de novo centers; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to the Company's services; the Company's ability to continue its growth, including in new markets; changes in laws and regulations applicable to the Company's business, in particular with respect to Medicare Advantage and Medicaid; the Company's ability to maintain its relationships with health plans and other key payers; any delay, modification or cancellation of government contracts; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs and the Company’s ability to comply with the covenants under the agreements governing its indebtedness; the Company’s ability to address the material weaknesses in its internal control over financial reporting; the Company's ability to recruit and retain qualified team members and independent physicians; risks related to future acquisitions; the Company’s ability to develop and maintain proper and effective internal control over financial reporting; and the impact of any prior period developments. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's reports filed with the SEC. All information provided in this Presentation is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law, and forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this Presentation. Use of Non-GAAP Financial Information Certain financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this Presentation, such as Adjusted EBITDA and Platform Contribution and margin thereof have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company’s management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. For this reason, these non-GAAP measures may not be comparable to other companies’ similarly labeled non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company’s audited financial statements, which have been filed by the Company with the SEC. A reconciliation for Adjusted EBITDA and Platform Contribution to the most directly comparable GAAP financial measures is included in this Presentation. A reconciliation of projected 2023 Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this Presentation because, without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

---

CareMax is Driven by a Mission to Deliver Best-in-Class Care 102K+ Medicare Advantage Members 62 CareMax Medical Centers 5-Stars CMS Quality Rating1 272K+ Total Members 10 States Note: As of June 30, 2023. Centers for Medicare & Medicaid Services 2022 Star rating across CareMax centers as of year-end 2022. Who We Are A value-based care delivery system that utilizes a technology-enabled platform and multi-specialty, whole person health model to deliver comprehensive, preventative and coordinated care for our members. Vision Transforming care to end disparity and create a sustainable healthcare system. Mission To improve lives through kindness, compassion, and better health.

---

Second Quarter 2023 Update Total membership of 272,500, up 210% year-over year Medicare Advantage membership of 102,500, up 177% year-over-year Revenue of $224.4 million, up 30% year-over-year Net loss of $32.4 million, compared to net loss of $9.4 million for 2Q22 Adjusted EBITDA of $7.0 million, compared to $7.2 million for 2Q221 Platform Contribution of $28.6 million, compared to $21.6 million for 2Q221 Medical Expense Ratio of 84.6%, compared to 73.6% for 2Q222 Ending cash of $54.6 million, $60.0 million of undrawn capacity on delayed draw term loan Adjusted EBITDA and Platform Contribution are non-GAAP metrics. For a reconciliation to the closest GAAP numbers, see the supplement to this presentation. Beginning with the three months ended June 30, 2023, for all periods presented, the Company has updated its calculation of the reconciliation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs. Medical Expense Ratio equals external provider costs divided by Medicare and Medicaid risk-based revenues.

---

Membership Breakdown Total Membership 272,500 Lives ~102,500 Medicare Advantage1 Full-Risk 36% Other VBC2 64% ~30,500 Medicaid Other VBC2 97% ~38,500 Commercial Full-Risk 90% Other VBC2 10% ~101,000 MSSP & ACO REACH MSSP 92% ACO REACH 8% Note: As of June 30, 2023. 99% of MA patients in value-based agreements. Other VBC includes Partial-Risk, Gain Share and Capitation-Only contracts.

---

Revising Revenue Outlook for Full Year 2023 Note: Year over year growth may not compute due to rounding. Adjusted EBITDA is a non-GAAP number. For a reconciliation to the closest GAAP number, see supplement to this presentation. A reconciliation of projected 2023 Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this Presentation, because without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this. Beginning with the three months ended June 30, 2023, for all periods presented, the Company has updated its calculation of the reconciliation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs. De novo pre-opening costs represent (1) incremental payroll costs from employees specifically associated with the operational, contractual, physical, or regulatory infrastructure for de novo centers, prior to their opening; (2) legal costs directly associated with the de novo centers, incurred prior to their opening, which includes services such as execution of leases, health plan contracts and other agreements; (3) other expenses related to diligence, design, permitting, and other “soft costs” at new sites; and (4) rent and facility expenses prior to center opening. De novo post-opening losses include center-level operating losses recognized at a de novo center until the center breaks even, up to 18 months after opening, which consist of revenue, external provider costs and cost of care allocated for the de novo center. FY 2023 Updated Guidance FY 2023 Previous Guidance FY 2022 YoY % growth Year-End Medicare Advantage Membership 110,000 to 120,000 110,000 to 120,000 93,500 18% to 28% Revenue $750 million to $800 million $700 million to $750 million $631 million 19% to 27% Adjusted EBITDA1 $25 million to $35 million $25 million to $35 million $19 million 31% to 83% De novo pre-opening costs and post-opening losses2 $25 million $25 million $13 million N/A

---

Second Quarter 2023 Financial Supplement

---

Reconciliation to Platform Contribution and Calculation of Medical Expense Ratio Gross profit reflects the reclassification of stock-based compensation expense previously included in corporate, general and administrative expenses, which decreased gross profit by $1.3 million for the three months ended June 30, 2022. Other adjustments include incremental costs primarily related to post-Business Combination integration initiatives. Reconciliation to Platform Contribution Calculation of Medical Expense Ratio

---

Reconciliation to Adjusted EBITDA1 Net Income to Adjusted EBITDA Bridge Beginning with the three months ended June 30, 2023, for all periods presented, the Company has updated its calculation of the reconciliation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs. Represents initial costs to set up public company processes, incremental compensation and vendor expenses identified as temporary or duplicative and expected to be rationalized in the short term, and legal and professional expenses outside of the ordinary course of business, which are being incurred as part of the Company’s efforts as it integrates the two privately held companies that were combined in the Business Combination. Includes all costs recognized in acquisition related costs in our consolidated statements of operations and incremental payroll compensation expense for employees directly associated with services to achieve synergies related to closed transactions. Components of Other and Pro forma adjustments are presented on the following slides.

---

Non-GAAP Adjustments Detail a) Represents consulting and legal costs directly associated with efforts related to integration of the two privately held companies that were combined in the Business Combination. b) Represents primarily vendor expenses identified as temporary or duplicative and/or expenses outside the ordinary course of business and not necessary to run our business. c) Includes payments to our third-party transaction advisory firm associated with transaction contracts, including the Steward transaction that was closed in November 2022. Also, costs include legal and accounting fees directly associated with contemplated or closed transactions. d) Includes incremental payroll compensation expense for employees directly associated with services to achieve synergies related to closed transactions. Components of Business Combination Integration Costs Components of Acquisition and Integration Related Costs Components of Other

---

Non-GAAP Adjustments Detail Components of Pro forma adjustments

---

Non-GAAP Financial Summary Beginning with the three months ended June 30, 2023, for all periods presented, the Company has updated its calculation of the reconciliation of Adjusted EBITDA on a retrospective basis to no longer add back certain compensation costs for stay-on bonuses and duplicative salaries previously included within the Business Combination integration costs. For the period ended June 30, 2021, the measure was calculated in a manner consistent with the concepts of Article 8 of Regulation S-X and represents Pro Forma Adjusted EBITDA. Non-GAAP Income Statement

---

Financial Impact of Prior Year Developments The first half of 2023 was also impacted by approximately $3.5 million of other favorable prior year developments in total revenue and approximately $3.3 million of other unfavorable prior year development in external provider costs. Related to retrospective update to historical 2022 membership at a Medicare MSO plan in the Space Coast of Florida. Estimated impact of unseasonal respiratory illness utilization in the fourth quarter of 2022. Unfavorable development due to data migration issues at a single Medicaid health plan. Impact of Select Prior Year Developments1 Prior year developments related to MSO membership at one health plan, an unseasonably early flu season, and lack of data at one Medicaid health plan impacted 1H23 revenue by $26.5 million and Adjusted EBITDA by $21.4 million1 2 3 4

---

Illustrative Underlying CareMax Centers Medical Expense Ratio Medical Expense Ratio equals external provider costs divided by Medicare and Medicaid risk-based revenues. See prior page for summary of select prior year developments. Reflects dilutive impact of full risk MSO membership on MER. 1H23 underlying CareMax centers Medical Expense Ratio was consistent with historical performance1 Impact of Select Prior Year Developments2 Impact of Total MSO Membership3 Impact of Benefit Cards Estimated Underlying CareMax Centers MER

---

Capitalization and Liquidity as of June 30, 2023 Diluted Share Count Net Debt (Cash) Excludes unvested warrants as of June 30, 2023.  Warrants have a strike price of $11.50 per share and (other than the Related warrants) are subject to a $18.00 redemption cap. Warrants are currently out of the money based on CareMax’s closing share price as of August 8, 2023. Represents contingent earnout shares related to Steward Acquisition following true-up. Reflects all unvested and outstanding RSUs and PSUs as of June 30, 2023. PSUs are included at an assumed 100% payout. Excludes options as they are currently out of the money based on CareMax’s closing share price as of August 8, 2023. Figures reflect principal amounts due as of June 30, 2023. Consists of outstanding debt on financed fixed assets and health plan collaboration loans.

---

Q&A

v3.23.2

Document And Entity Information	Aug. 09, 2023
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 09, 2023
Entity Registrant Name	CareMax, Inc.
Entity Central Index Key	0001813914
Entity Emerging Growth Company	true
Securities Act File Number	001-39391
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0992224
Entity Address, Address Line One	1000 NW 57 Court
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33126
City Area Code	786
Local Phone Number	360-4768
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Ex Transition Period	false
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	CMAX
Security Exchange Name	NASDAQ
Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	CMAXW
Security Exchange Name	NASDAQ

---